Needham Maintains Buy on TransMedics Group, Raises Price Target to $174
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $166 to $174.
Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $166 to $174.